Targeting diseases with unmet needs and significant public health burdens

Brii Bio began with a focus in infectious disease because the need is great in China and the threat is global. Infectious diseases are a leading cause of death and disability worldwide, contributing significantly to the increasing costs of health care.

Our passion for delivering world class research and technological innovation does not end here. We are taking aim at other diseases with significant unmet needs that have a dramatic impact on patients’ lives.

This includes diseases of the central nervous system. These disorders are among the most common in the world, affecting all countries. Emerging science has opened the door to novel ways to treat these diseases and our business model is strategically designed to identify transformative innovation and deliver it to patients.

Our goal is to pursue disease areas that present significant therapeutic challenges and, if there is the potential to redefine treatment and make a significant and unique contribution to health, Brii Bio will take a leadership role.

>PIPELINE

We are taking a leadership position in the race to deliver a functional cure for chronic hepatitis B infection (HBV) in China, where the disease is a significant public health issue and silent epidemic affecting more than 90 million people.

HBV is one of the world’s most significant infectious disease threats, with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and is exceedingly difficult to cure, with many patients going on to develop liver cancers. An estimated 900,000 people die each year from complications of chronic HBV

The most significant public-health challenge in a century, COVID-19 has rapidly spread around the world, drastically impacting global health and economies unlike anything experienced in recent times. Its effect will be felt for years to come.

There are no borders when fighting infectious diseases and collaboration is key to finding therapeutic solutions that target SARS-CoV-2, the virus that causes COVID-19, and ensuring we are prepared to handle future outbreaks. We are leveraging our expertise in infectious disease and working with our partners to advance multiple candidates for prevention and treatment of COVID-19, with a goal of delivering an effective therapy to benefit people around the world.

A more difficult to treat form of tuberculosis (TB) – an infection that destroys the lung – multidrug-resistant tuberculosis (MDR-TB) is caused by bacteria that do not respond to existing first-line treatments. While MDR-TB can be treated and cured using second-line drugs, these treatments are long and come with dangerous side effects.

According to the World Health Organization, MDR-TB remains a public health crisis and a health security threat. Each year, on average, MDR-TB affects nearly a half a million people globally and is responsible for 240,000 deaths. One third of the world’s MDR-TB infections occur in China.

Once-daily oral single tablet regimens are the current standard of care and have successfully addressed the multiple pill burden, a historical issue in HIV treatment. Today, people with HIV increasingly desire the freedom of living a normal life and prefer treatment options that do not remind them daily of their HIV infection and the risk of developing other diseases. We are focused on identifying unique treatment options to reduce the burden of disease, improve quality of life, ensure better adherence to therapy and lower the total cost of care. 

Antimicrobials resistance (AMR) is one of the greatest threats we face as a global community. Global health agencies have warned that by 2050 AMR could cause 10 million deaths each year and significant damage to the world’s economy. At least 700,000 people die each year due to antibiotic-resistant infections.

China bears a disproportional burden as a result of over-prescription of antibiotics and more prevalent multi-drug resistant infections. With few or no options available to treat these infections, patients suffer, health care costs increase and far too many people die. 

While investment in antibiotic research and development has diminished in recent years, we are working with our partners to address this public health threat and identify innovations to meet not only today’s threats but tomorrow’s as well.



up
×